twitter
en POLSKI
eISSN: 2719-3209
ISSN: 0023-2157
Klinika Oczna / Acta Ophthalmologica Polonica
Current issue Archive Videos Articles in press About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
1/2011
vol. 113
 
Share:
Share:
abstract:
Case report

Combined pharmacological-surgical treatment in exudative age-related macular degeneration

Małgorzata Figurska
1
,
Jacek Robaszkiewicz
1
,
Agnieszka Bogdan-Bandurska
1

  1. Klinika Okulistyczna Wojskowego Instytutu Medycznego w Warszawie
Klinika Oczna 2011, 113 (1): 56-59
Online publish date: 2011/04/17
View full text Get citation
 
Introduction
The aim of this paper is to present the early phase of treating exudative age-releted macular degeneration (AMD) – coexisting witch vitreoretinal pathology – with combined pharmacological-surgical therapy.

Material and methods
Our observation is based on one clinical case of combined therapy: pars planavitrectomy (PPV) and one intravitrealranibizumab injection. Observation is being carried on larger patient group according to the treatment scheme presented in this paper.

Results
In this case described combined pharmacological-surgical therapy allowed a significant improvement in visual acuity and closure of choroidal neovascularization (CNV), leakage confirmed by fluorescein angiography (FA) and optical coherence tomography (AMD). The treatment is being continued – another ranibizumab injection according to PRONTO study reinjection criteria.

Conclusions
The pathomechanism of exudative AMD and coexistance of vitreoretinal pathology implications confirm reasonability of combined therapy.Due to actual clinical studies: the pharmacological -surgical treatment reduces the number of required intravitreal anti-VEGF agents injections.To confirm this observation we need to perform large randomised clinical studies.

keywords:

exudative form of age-related macular degeneration (AMD), combined therapy, ranibizumab

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.